+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Doxorubicin"

From
From
From
From
From
Peripheral T-Cell Lymphoma - Epidemiology Forecast - 2032 - Product Thumbnail Image

Peripheral T-Cell Lymphoma - Epidemiology Forecast - 2032

  • Report
  • September 2022
  • 117 Pages
  • Global
From
From
polatuzumab vedotin - Product Thumbnail Image

polatuzumab vedotin

  • Report
  • October 2018
  • 18 Pages
  • Global
From
Kinenza - Product Thumbnail Image

Kinenza

  • Report
  • October 2018
  • 17 Pages
  • Global
From
Global Doxorubicin Market 2023-2027 - Product Thumbnail Image

Global Doxorubicin Market 2023-2027

  • Report
  • March 2023
  • 157 Pages
  • Global
From
From
Drug Delivery in Cancer - Technologies, Markets & Companies - Product Thumbnail Image

Drug Delivery in Cancer - Technologies, Markets & Companies

  • Report
  • November 2021
  • 747 Pages
  • Global
From
Global Doxorubicin Market Report and Forecast 2023-2031 - Product Thumbnail Image

Global Doxorubicin Market Report and Forecast 2023-2031

  • Report
  • May 2023
  • 140 Pages
  • Global
From
Loading Indicator

Doxorubicin is an oncology drug used to treat a variety of cancers, including leukemia, lymphoma, and breast, ovarian, and bladder cancer. It is a type of anthracycline antibiotic, derived from Streptomyces peucetius, and works by interfering with the growth of cancer cells. It is administered intravenously, and is often used in combination with other drugs. Doxorubicin is one of the most widely used chemotherapy drugs, and is often used in combination with other drugs to treat a variety of cancers. It is also used to treat Kaposi's sarcoma, a type of skin cancer. Side effects of doxorubicin include nausea, vomiting, hair loss, and an increased risk of infection. The doxorubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more